Cargando…

P1046: TREATMENT COMPARISON OF HYDROXYUREA VS RUXOLITINIB IN ESSENTIAL THROMBOCYTHEMIA (ET): A MATCHED COHORT ANALYSIS

Detalles Bibliográficos
Autores principales:	Grunwald, Michael, Ritchie, Ellen, Rumi, Elisa, Assad, Albert, Hamer-Maansson, J.E., Yu, Jingbo, Braunstein, Evan, Passamonti, Francesco
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2023
Materias:	Posters
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10431511/ http://dx.doi.org/10.1097/01.HS9.0000971080.94647.fb

Ejemplares similares

Ruxolitinib for essential thrombocythemia?
por: Bose, Prithviraj, et al.
Publicado: (2017)

P1032: CHARACTERISTICS AND CLINICAL OUTCOMES IN PATIENTS (PTS) WITH POLYCYTHEMIA VERA (PV) RECEIVING RUXOLITINIB (RUX) AFTER HYDROXYUREA (HU): A LONGITUDINAL ANALYSIS FROM REVEAL
por: Gerds, Aaron T., et al.
Publicado: (2023)

PB2185: EFFECT OF NEW OR WORSENING ANEMIA ON CLINICAL OUTCOMES IN PATIENTS WITH MYELOFIBROSIS (MF) TREATED WITH RUXOLITINIB (RUX): A POST HOC ANALYSIS OF THE COMFORT-I AND -II TRIALS
por: Al-Ali, Haifa Kathrin, et al.
Publicado: (2023)

Ruxolitinib for the Treatment of Essential Thrombocythemia
por: Gunawan, Arief, et al.
Publicado: (2018)

P1045: DISEASE PROGRESSION AND LEUKEMIC TRANSFORMATION IN PATIENTS WITH LOWER-RISK MYELOFIBROSIS: AN ANALYSIS FROM MOST
por: Komrokji, Rami S., et al.
Publicado: (2023)

Mutation landscape in patients with myelofibrosis receiving ruxolitinib or hydroxyurea
por: Pacilli, Annalisa, et al.
Publicado: (2018)

A randomized phase 3 trial of interferon-α vs hydroxyurea in polycythemia vera and essential thrombocythemia
por: Mascarenhas, John, et al.
Publicado: (2022)

EGNOS 1046 Maritime Service Assessment
por: Ibáñez Segura, Deimos, et al.
Publicado: (2020)

An Ulceronecrotic Foot Lesion in a Patient with Essential Thrombocythemia: Successful Treatment with Hydroxyurea
por: Kato, Tokue, et al.
Publicado: (2012)

Calreticulin mutant mice develop essential thrombocythemia that is ameliorated by the JAK inhibitor ruxolitinib
por: Shide, K, et al.
Publicado: (2017)

A phase 2 study of ruxolitinib, an oral JAK1 and JAK2 inhibitor, in patients with advanced polycythemia vera who are refractory or intolerant to hydroxyurea
por: Verstovsek, Srdan, et al.
Publicado: (2014)

Adding hydroxyurea in combination with ruxolitinib improves clinical responses in hyperproliferative forms of myelofibrosis
por: Pugliese, Novella, et al.
Publicado: (2019)

Successful Management of Hydroxyurea-induced Leg Ulcers in Essential Thrombocythemia: Report of 3 Cases
por: Rahal, Jihane Abou, et al.
Publicado: (2013)

Prognostic value of modified criteria for hydroxyurea resistance or intolerance in patients with high‐risk essential thrombocythemia
por: Park, Young Hoon, et al.
Publicado: (2023)

Unusual genome complexity in Lactobacillus salivarius JCM1046
por: Raftis, Emma J, et al.
Publicado: (2014)

Rapid and robust reversion to essential thrombocythemia on treatment with Decitabine in a case of hydroxyurea‐induced t‐MDS/AML
por: Horton, Joshua D., et al.
Publicado: (2015)

S168: PELABRESIB (CPI-0610) MONOTHERAPY IN PATIENTS WITH HIGH-RISK ESSENTIAL THROMBOCYTHEMIA REFRACTORY OR INTOLERANT TO HYDROXYUREA: PRELIMINARY RESULTS FROM MANIFEST STUDY
por: Passamonti, Francesco, et al.
Publicado: (2023)

PB2215: HYDROXYUREA-INDUCED CUTANEUS ADVERSE EVENTS IN PATIENTS WITH ESSENTIAL THROMBOCYTHEMIA: A SINGLE-CENTER EXPERIENCE
por: Peña, Amaia Lopez, et al.
Publicado: (2023)

Matching-adjusted indirect comparison of the pelabresib-ruxolitinib combination vs JAKi monotherapy in myelofibrosis
por: Gupta, Vikas, et al.
Publicado: (2023)

Acquired Melanonychia in Chilean Patients with Essential Thrombocythemia Treated with Hydroxyurea: A Report of 7 Clinical Cases and Review of the Literature
por: Murray, Nigel P., et al.
Publicado: (2013)

P1029: MATCHING-ADJUSTED INDIRECT COMPARISON (MAIC) OF PELABRESIB (CPI-0610) IN COMBINATION WITH RUXOLITINIB VS RUXOLITINIB OR FEDRATINIB MONOTHERAPY IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK MYELOFIBROSIS
por: Gupta, V., et al.
Publicado: (2022)

Predictors of Response to Hydroxyurea and Switch to Ruxolitinib in HU-Resistant Polycythaemia VERA Patients: A Real-World PV-NET Study
por: Palandri, Francesca, et al.
Publicado: (2023)

Coronary Artery Bypass Grafting: 30-Day Operative Morbidity Analysis in 1046 Patients
por: AlWaqfi, Nizar R., et al.
Publicado: (2012)

Economic costs of diabetes in the U.S. in 2012. Diabetes Care 2013;36:1033–1046
Publicado: (2013)

1046 Economic Burden of Herpes Zoster by Age Group in Immunocompetent Patients in the United States
por: Gatwood, Justin, et al.
Publicado: (2014)

Long-term and low-dose of busulfan is a safe and effective second-line treatment in elderly patients with essential thrombocythemia resistant or intolerant to hydroxyurea
por: Renso, Rossella, et al.
Publicado: (2018)

Ruxolitinib rechallenge in combination with hydroxyurea is effective in reverting cachexia and reducing blood transfusion demand and splenomegaly symptoms in a patient with primary myelofibrosis
por: Cerchione, Claudio, et al.
Publicado: (2017)

Clinical and dermoscopic features of surgically treated melanocytic nevi: a retrospective study of 1046 cases
por: Li, Qian-Xi, et al.
Publicado: (2019)

Survival expectation after thrombosis and overt-myelofibrosis in essential thrombocythemia and prefibrotic myelofibrosis: a multistate model approach
por: Carobbio, Alessandra, et al.
Publicado: (2023)

Essential thrombocythemia
por: Brière, Jean B
Publicado: (2007)

Management of thrombocythemia
por: Gowin, Krisstina, et al.
Publicado: (2014)

Practice-relevant revision of IPSET-thrombosis based on 1019 patients with WHO-defined essential thrombocythemia
por: Barbui, T, et al.
Publicado: (2015)

Impact of ruxolitinib on survival of patients with myelofibrosis in the real world: update of the ERNEST Study
por: Guglielmelli, Paola, et al.
Publicado: (2022)

Real‐world analysis of main clinical outcomes in patients with polycythemia vera treated with ruxolitinib or best available therapy after developing resistance/intolerance to hydroxyurea
por: Alvarez‐Larrán, Alberto, et al.
Publicado: (2022)

MD, Runs 1040 et 1046, Test des conditions de mesure des hauteurs effectives et de calibration des moniteurs de luminosité.
por: Hémery, J Y, et al.
Publicado: (1979)

MD, run 1040 and 1046, Development of a new program for automatic vertical beam steering to optimise luminosity
por: Hémery, J Y, et al.
Publicado: (1979)

Environmental and occupational respiratory diseases – 1046. Lung function among the workers exposed to rubber factory in West Bengal
por: Pandey, Naren, et al.
Publicado: (2013)

The Prediction Model of Risk Factors for COVID-19 Developing into Severe Illness Based on 1046 Patients with COVID-19
por: Lian, Zhichuang, et al.
Publicado: (2021)

P1046: SEVERE COMPLICATIONS IN JAK2 V617F POSITIVE PEDIATRIC PATIENTS WITH MYELOPROLIFERATIVE NEOPLASMS
por: Novak, W., et al.
Publicado: (2022)

WCN23-1046 PATHOGENETIC ASPECTS OF THE DEVELOPMENT OF ACUTE KIDNEY INJURY IN COVID 19: OWN OBSERVATION DATA
por: GARAZHAYEVA, L., et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_pb7h91n346t53v9bib06mqnkh7